Prognostic impact and site-specific efficacy of systemic therapies in locally advanced or metastatic urothelial carcinoma: in an era of expanding therapeutic options
{{output}}
Objective: Combination therapy with enfortumab vedotin (EV) and pembrolizumab has shown superior overall survival (OS) compared to platinum-based chemotherapy in advanced urothelial carcinoma (UC). Given the expanding landscape o... ...
